The nonsense-mediated mRNA decay (NMD) pathway selectively eliminates aberrant transcripts containing premature translation termination codons and regulates the levels of a number of physiological mRNAs. NMD modulates the clinical outcome of a variety of human diseases, including cancer and many genetic disorders, and may represent a target for therapeutic intervention. Here, we have developed a new multicolored bioluminescence-based reporter system that can specifically and effectively assay NMD in live human cells. Using this reporter system, we conducted a robust high-throughput smallmolecule screen in human cells and, unpredictably, identified a group of cardiac glycosides, including ouabain and digoxin, as potent inhibitors of NMD. Cardiac glycoside-mediated effects on NMD are dependent on binding and inhibiting the sodiumpotassium ATPase on the plasma membrane and subsequent elevation of intracellular calcium levels. Induction of calcium release from the endoplasmic reticulum also leads to inhibition of NMD. Thus, this study reveals intracellular calcium as a key regulator of NMD and has implications for exploiting NMD in the treatment of disease.
The NMD pathway selectively degrades mRNAs harboring premature translation termination codons (PTCs) and, in so doing, guards cells against insults from potentially deleterious truncated proteins. In addition to eliminating faulty mRNA transcripts, NMD regulates the levels of many physiological mRNAs possessing features that are recognized by the NMD machinery 1, 2 . By modulating the activity of NMD, cells can enact gene expression programs crucial for normal development or for responding to environmental cues such as hypoxia and amino acid deprivation 3, 4 . Furthermore, approximately one-third of human genetic diseases are manifestations of PTC mutations 5 , and whole-genome sequencing has recently uncovered numerous somatic nonsense mutations in tumor samples 6 . Thus, NMD has become an attractive target for the treatment of many human diseases. For example, inhibiting NMD may alleviate the symptoms of certain genetic diseases caused by PTCs if the truncated protein products are functional or partially functional hypomorphs 7, 8 . NMD inhibition also represents a promising cancer therapeutic strategy 7 . Cancer cells probably have an elevated dependency on NMD for survival owing to their production of many nonsense mRNAs as a result of their intrinsic genomic instability. Thus, inhibiting NMD may lead to preferential killing of cancer cells. Moreover, inhibiting NMD may also result in production of new antigens on tumor cells that could induce an anticancer immune response 9 .
RESULTS

Development of a dual-color, bioluminescence-based NMD reporter system
To investigate the NMD pathway and to begin to develop NMD-targeting therapeutics, we constructed a multicolored, bioluminescencebased reporter for assaying NMD in mammalian cells ( Fig. 1a and Supplementary Fig. 1 ). This reporter comprises a single expression vector containing two separate transcription units, each with a luciferase inserted into a TRB minigene (encoding T cell receptor-β) at the same position within the second exon. The first transcription unit consists of a PTC-containing TRB minigene fused to click beetle red luciferase (CBR-TCR(PTC)). The second unit contains a wild-type (WT) TRB minigene fused to click beetle green 99 luciferase (CBG99, hereafter referred to as CBG for simplicity) (CBG-TCR(WT)). Expression of both fusion reporter genes is controlled by separate cytomegalovirus (CMV) promoters, splice sites and polyadenylation signals of identical sequences. A sequence encoding a hemagglutinin tag was included in the first exon of the fusion reporter genes, which provides an independent method to detect the translated fusion protein products through western blotting. PTCs in the well-characterized TRB minigene are known to elicit robust NMD (but not 100% efficient, as is the case for other reporter genes examined) 10, 11 . The CBR-TCR(PTC) and CBG-TCR(WT) transcription units share >99% sequence identity at the DNA, pre-mRNA and mRNA levels (reporter sequence is given in Supplementary Fig. 2 ). Using this dual-colored reporter, NMD can be quantified by the ratio of CBR activity to CBG activity, with an increase in the CBR/CBG (red/green) ratio representing inhibition of NMD. Here, the CBR luciferase activity serves as an indirect measure of the steady-state levels of the CBR-TCR(PTC) fusion mRNA, which is targeted for degradation by NMD, whereas the CBG luciferase activity reflects the steady-state levels of the CBG-TCR(WT) fusion mRNA, which is unresponsive to NMD. The use of CBG-TCR(WT) as an internal control in the same cell ensures that changes in the CBR/CBG ratio reflect effects specifically attributable to NMD and not indirect effects that result from variations in reporter DNA delivery or from effects on cell viability or various steps of gene expression such as transcription, splicing, polyadenylation and translation. The use of the highly sensitive and closely related red-emitting CBR and green-emitting CBG luciferases, combined with a spectral deconvolution algorithm for unmixing CBR and CBG signals, allows rapid and accurate measurement of their respective activities simultaneously in a single reaction with the same d-luciferin substrate 12 .
To validate the NMD reporter system, we generated a human osteosarcoma cell line (U2OS) stably expressing the reporter. Western blot results indicate that whereas the CBG-TCR(WT) fusion protein was efficiently expressed, the basal level of the CBR-TCR(PTC) truncated protein was barely detectable (Fig. 1b) . This result is consistent with the prediction that CBR-TCR(PTC) mRNA, but not CBG-TCR(WT) mRNA, is targeted for NMD. Treatment with caffeine, a potent (but not specific) inhibitor of the kinase activity of the NMD factor SMG1, restored the CBR-TCR(PTC) protein levels. Bioluminescence imaging revealed that the CBR/CBG ratio increased by approximately threefold following caffeine treatment ( Fig. 1c) . Notably, quantitative RT-PCR (RT-qPCR) analysis performed with primers specific to CBR or CBG luciferases in the reporter revealed a similar increase in the ratio of CBR-TCR(PTC) to CBG-TCR(WT) reporter mRNAs ( Fig. 1d and Supplementary Table 1 ). Furthermore, shRNA-mediated knockdown of the NMD factors SMG1, UPF1 and UPF2 also inhibited NMD of the reporter, as measured by western blotting, bioluminescence assay and RT-qPCR ( Fig. 1e-h) . Taken together, these data demonstrate that this mechanism-based NMD reporter system faithfully recapitulates the characteristics of NMD in human cells and is expected to be specific, rapid and sensitive.
A high-throughput small-molecule compound screen identifies cardiac glycosides as potent inhibitors of NMD Using the reporter system described above, we next performed a highthroughput screen to identify drug candidates that can alter NMD activity in human cells. We used the PHARMAKON 1600 library (Online Methods), which contains a diverse array of 1,600 clinically evaluated compounds, as the source of small molecules in the hope of repurposing existing drug candidates to fast-track the drug development process. We seeded human U2OS cells containing the dualcolored NMD reporter onto 96-well plates and added individual drugs to each well at a concentration of 10 µM, along with appropriate controls. Twenty-four hours after drug treatment, we added d-luciferin to the medium, followed by bioluminescence imaging and spectral unmixing to obtain CBR and CBG signals ( Fig. 2a) . We calculated a Z′ factor of 0.77 for the reporter assay, demonstrating the robustness of the strategy (Online Methods). The majority of the compounds in the library exhibited little or no effect on NMD of the reporter ( Fig. 2b and Supplementary Table 2 ). However, we identified 8 candidate inhibitors and 14 candidate enhancers of NMD by quartile analysis after employing stringent criteria for hit selection 13 ( Fig. 2b and Supplementary Table 3 ). Focusing on NMD inhibitors in this study, we confirmed the effects of seven of the inhibitor hits in follow-up analysis and found that each validated compound inhibited NMD in a dose-dependent manner (data not shown). Notably, the top five verified hits, including digitoxin, digoxin, lanatoside C, proscillaridin and ouabain, are all cardiac glycosides (CGs), which inhibit sodiumpotassium ATPase (Na + /K + -ATPase) in cells 14 (Fig. 2b) .
At the initial screening concentration (10 µM), all CGs increased CBR signal compared to DMSO treatment, but these drugs also decreased CBG signal, potentially owing to nonspecific toxic effects shRNA: on cell viability ( Supplementary Table 2 ). However, we identified a lower concentration for each drug at which the CBR activity was still markedly increased and the CBG activity remained largely unaffected ( Fig. 3a) . At these modest concentrations, these drugs did not significantly affect general translation in cells and had only a mild inhibitory effect on cell viability ( Supplementary Fig. 3a,b) . Because CBR and CBG proteins are relatively stable, the inhibitory effects of CGs on the signal generated by the NMD reporter was time dependent, increasing over the 24-h treatment period; CG-mediated blockade of NMD was fully concentration dependent, with reportergenerated half-maximum effective concentration values of ~70 nM and ~200 nM for ouabain and digoxin, respectively ( Supplementary  Fig. 4a,b) . Notably, our bioluminescence imaging results were corroborated by western blot and reporter-specific RT-qPCR analyses of the CBR-TCR(PTC) and CBG-TCR(WT) protein and mRNA levels, respectively (Fig. 3b,c) .
To further validate the effects of CGs on NMD using an independent NMD model system, we used the human Calu-6 cell line, which expresses a PTC-containing nonsense mRNA of endogenous p53 (refs. 15,16) . We first treated Calu-6 cells with CGs for 16 h. Subsequently, we added the transcription inhibitor actinomycin D to block new mRNA synthesis and determined the levels of p53 mRNA by RT-qPCR at 0 h and 6 h after actinomycin D treatment. All five CGs significantly increased the stability of the mutant p53 transcript compared with DMSO ( Fig. 3d) . In further support of the idea that CGs inhibit NMD, we observed increased stability of wild-type endogenous mRNA targets of NMD, including UPP1, ATF4, PIM3 and PISD, in Calu-6 cells after treatment with ouabain. In contrast, the stability of endogenous ORCL transcripts, which are not targeted by NMD, was unaffected under the same conditions [17] [18] [19] [20] (Fig. 3e) . It has been previously shown that the mRNA levels of many of the NMD factors, such as SMG1, UPF1, UPF2, UPF3B, SMG5, SMG6 and SMG7, are controlled by NMD via an autoregulatory loop, as they are themselves targets of NMD 20, 21 . Consequently, these transcripts are upregulated upon ablation of NMD activity 21, 22 . If CGs inhibit NMD, one would expect an increase in these NMD factor transcript levels after CG treatment. Indeed, we found that ouabain treatment led to npg upregulation of all of these autoregulated NMD factors except SMG6 (whose upregulation was also less obvious upon NMD inhibition after UPF1 knockdown in previous studies 21, 22 ) (Supplementary Fig. 4c ).
Taken together, these data suggest that CGs have a previously unrecognized ability to inhibit NMD in human cells.
Na + /K + -ATPase is a robust regulator of NMD As the Na + /K + -ATPase (composed of a catalytic α subunit and a structural β subunit, each with various isoforms, and a regulatory γ subunit) is the only known pharmacological target of the identified CGs, our results suggest that CGs inhibit NMD via the sodium-potassium pump 23 . Consistent with this idea, our reporter assay indicates that mouse skin fibroblasts, which express a naturally CG-resistant α 1 subunit of Na + /K + -ATPase, exhibited more than 100 times greater resistance to ouabain compared to human cells, in which all four isoforms of the α subunit have a much higher affinity for CGs 24 (Fig. 4a) .
In contrast, NMD of the reporter exhibited a similar level of sensitivity to caffeine in both human and mouse cells (Fig. 4a) . Moreover, overexpression in human cells of the rat α 1 subunit of Na + /K + -ATPase, which also has a low affinity for CGs, abrogated the inhibitory effects of ouabain on NMD (Fig. 4b) . In contrast, expression of a similar level of rat α 3 subunit of Na + /K + -ATPase, which is sensitive to CGs 24,25 , did not cause resistance of NMD to ouabain ( Fig. 4b and Supplementary   Fig. 5a ). Furthermore, expression of a CG-resistant mutant version of the human α 1 subunit also prevented the CG-mediated inhibition of NMD, whereas the wild-type protein failed to do so ( Fig. 4c and  Supplementary Fig. 5b) .
To further demonstrate that CGs inhibit NMD through their binding and inhibition of Na + /K + -ATPase, we generated a catalytically inactive mutant of the rat α 1 subunit (D376E) that has diminished binding and hydrolysis of ATP 25 . Unlike the wild-type rat α 1 subunit, expression of this mutant in human cells did not cause resistance of NMD to CGs, indicating that blockade of the sodium-potassium pump enzymatic activity is necessary for efficient CG-induced inhibition of NMD ( Fig. 4d  and Supplementary Fig. 5c ). Taken together, these data suggest that Na + /K + -ATPase is a robust regulator of NMD in mammalian cells and that CGs inhibit NMD through binding and inhibiting this sodiumpotassium pump. Given the essential role of Na + /K + -ATPase for cell viability, the observation that CGs inhibited NMD at concentrations where no obvious decrease in CBG activity or cell viability was observed suggests that partial inhibition of the sodium-potassium pump is sufficient to abolish NMD ( Fig. 3 and Supplementary Fig. 3b) .
Intracellular calcium is a key regulator of NMD Because a major effect of Na + /K + -ATPase inhibition is elevation of intracellular calcium levels 14 , we hypothesized that the inhibition of npg NMD by the CGs is caused by increased intracellular calcium concentration. To test this, we treated U2OS reporter cells with ouabain and Bapta-AM, a cell-penetrating intracellular calcium chelator, to buffer cytosolic free calcium transients. Bapta-AM reversed the inhibitory effects of ouabain on NMD, although Bapta-AM treatment alone did not affect NMD (Fig. 4e) . This suggests that calcium indeed mediates the inhibitory effects of CGs on NMD. To further establish the regulation of NMD by calcium, we treated reporter cells with multiple drugs that raise intracellular calcium levels by independent mechanisms. We found that thapsigargin, which induces the release of calcium stores from endoplasmic reticulum into the cytoplasm, abrogated NMD in the reporter cells and that this effect was also ablated by Bapta-AM (Fig. 4f) . Furthermore, the calcium ionophore A23187, which also increases intracellular calcium concentration, exhibited similar inhibitory effects on NMD (data not shown). Taken together, these results suggest that calcium is a crucial regulator of NMD in human cells.
DISCUSSION
In this report, we developed a highly effective NMD bioluminescent reporter system, and using this reporter, we identified CGs as potent inhibitors of NMD. Our studies also led to the discovery of a calciummediated NMD regulatory pathway (Fig. 4g) . These findings have implications in both basic and translational research. Our results suggest a new therapeutic strategy for NMD inhibition by manipulating intracellular calcium levels. CGs or derivatives with low toxicity might be effective in treating certain genetic diseases, such as cystic fibrosis and Duchenne's muscular dystrophy, wherein truncated protein products encoded by the corresponding nonsense mRNAs are fully or partially functional 7, 8 . It should be noted that the concentrations of CGs we used in this study to achieve more complete NMD inhibition without causing significant cellular toxicity (for example, 500 nM for digoxin and 175 nM for ouabain) are much higher than standard clinical doses used for treatment of cardiac failure 26 . Thus, acute use of these drugs at our current experimental working concentrations cannot directly translate to the clinic owing to in vivo toxic effects. However, the benefits of partial NMD inhibition with chronic treatment at clinically relevant doses may potentially be efficacious, but this will require further clinical pharmacology studies. Other drugs or derivatives of CGs that can efficiently increase intracellular calcium with low toxicity profiles may potentially be used as clinical agents for NMD inhibition. Notably, our results may also suggest a possible explanation for the anticancer properties previously observed for CGs in both epidemiological and laboratory studies 14 . A recent study indicates that the same CGs we identified as inhibitors of NMD are potent inducers of an anticancer immune response at concentrations similar to those used in this study 27 . Mechanistically, inhibition of NMD may result in the synthesis of new tumor-specific antigens that could induce antitumor immunity 9 . Given the antitumor immunity observed in mice after NMD disruption 9 and the inhibitory effects of CGs on NMD shown in this study, it is possible that the antitumor immunity induced by these drugs results, in part, from their chronic effects on NMD. However, the functions of NMD in cancer cells are likely to be complex, and further in-depth studies are needed to determine the potential of NMD inhibition as a cancer therapeutic strategy.
As a key secondary messenger in the cell, calcium is involved in a wide range of signaling pathways. Fluctuation of intracellular calcium concentration dictates many physiological processes, such as development, proliferation, synaptic transmission and immune activation.
Our identification of the link between intracellular calcium and NMD suggests that NMD is more dynamically regulated in cells than previously thought. Furthermore, given the role of NMD in regulating the levels of many physiological mRNAs, our study also suggests a novel mechanism for the calcium-mediated gene expression programs 3,28-34 . It is not clear at present how intracellular calcium regulates NMD in cells. Calcium may directly bind and regulate the activities and functions of NMD factors. Alternatively, it may indirectly regulate NMD through calcium-dependent signaling molecules such as kinases and phosphatases. Notably, Johansson and Jacobson 35 have previously shown in yeast cells that elevated levels of another divalent cation, magnesium, inhibit NMD by promoting translation readthrough at stop codons. Unlike magnesium, intracellular calcium apparently does not promote translation readthrough, as treatment with CGs or thapsigargin resulted in the production of a truncated protein terminated at the PTC in the CBR-TCR(PTC) reporter ( Fig. 3b and data not shown). Elucidating the precise mechanism of this calcium-mediated NMD regulation will not only broaden understanding of how NMD activity is fine-tuned but also provide crucial insights into the cellular processes that are dependent on this regulation.
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